Indicated for: acne vulgaris
Route of administration: cutaneous
Substance: erythromycin + tretinoin (macrolide antibiotic + retinoid)
ATC: D10AF52 (Dermatologicals | Anti-acne preparations for topical use | Antiinfectives for treatment of acne)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
The combination of erythromycin and tretinoin is used to treat acne vulgaris, particularly in mild to moderate cases. It combines the effects of an antibiotic (erythromycin) with those of a retinoid (tretinoin), providing a synergistic approach to reducing inflammation, bacteria, and acne lesions.
- Erythromycin is a macrolide antibiotic that works by inhibiting the growth of bacteria involved in acne, such as Cutibacterium acnes. It reduces inflammation and prevents the formation of new acne lesions.
- Tretinoin is a vitamin A derivative that accelerates cell turnover, reduces the formation of comedones (blackheads and whiteheads), and improves skin texture.
This combination is available as a gel or cream and is applied topically, usually once daily in the evening, on clean and dry skin.
Common side effects include local irritation, redness, peeling, burning sensation, or dryness of the skin. These reactions are usually temporary and subside as the skin adapts to the treatment. It is important to avoid excessive sun exposure and use sunscreen, as tretinoin can increase skin sensitivity to UV rays.
Patients should strictly follow their doctor’s instructions and avoid using other irritating products (such as harsh exfoliants or alcohol-based products) during treatment. The combination is not recommended for pregnant or breastfeeding women due to the risks associated with tretinoin.